<DOC>
	<DOCNO>NCT01911520</DOCNO>
	<brief_summary>During laparoscopic bariatric surgery , adequate muscle relaxation important maintain good surgical condition . To achieve muscle relaxation , neuromuscular transmission block agent , rocuronium ( Esmeron速 ) use . It sometimes happen still neuromuscular block activity leave patient awaken anesthesia . This call residual curarization know cause postoperative complication impairment respiratory function . Sugammadex ( Bridion速 ) novel drug selectively bind rocuronium ( Esmeron速 ) . It allow reverse neuromuscular transmission block activity . Until , study sugammadex perform non-obese patient . Obese patient high risk suffer post-operative respiratory failure . Therefore vital avoid residual curarization . Sugammadex might important factor . Obese patient large total body weight different ideal body weight . Recent research demonstrate dose neuromuscular block agent rocuronium ( Esmeron速 ) need calculated patient ' Ideal Body Weight rather Total Body Weight . At moment data available dose-response relationship sugammadex morbidly obese patient . We hypothesize morbidly obese patient sugammadex dose ideal bodyweight , instead total bodyweight .</brief_summary>
	<brief_title>Dose Finding Study Effective Reversal Deep Rocuronium-induced Neuromuscular Block With Sugammadex Morbidly Obese Patients</brief_title>
	<detailed_description>Flowchart : 72 participant Stratification BMI &lt; 50 BMI &gt; 50 Randomization Randomization TBW IBW TBW IBW 2mg/kg n=9 2mg/kg n=9 2mg/kg n=9 2mg/kg n=9 4mg/kg n=9 4mg/kg n=9 4mg/kg n=9 4mg/kg n=9 TBW : Total Body Weight IBW : Ideal Body Weight</detailed_description>
	<mesh_term>Rocuronium</mesh_term>
	<criteria>Inclusion criterion : ASA IIIIII Age 18 65 year Male female BMI &gt; 30 Exclusion criterion : Renal failure Liver dysfunction Breastfeeding female patient , female patient without reliable contraception Neuromuscular disease Malignant hyperthermia family history malignant hyperthermia Allergy neuromuscular block agent medication use general anesthesia Infectious disease patient fever Patients already receive rocuronium sugammadex day study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2013</verification_date>
</DOC>